MOUNTAIN VIEW, Calif., Dec. 21, 2010 /PRNewswire/ — Based on
its recent analysis of the surface functionalization technologies
market, Frost & Sullivan recognizes Cambridge, Mass.-based
Semprus BioSciences with the 2010 Enabling Technology of the
Year Award for Surface Functionalization Technologies. The
company’s Semprus Platform is a high-performance biofunctional
surface modification designed to reduce the complications
associated with implanted medical devices while improving
healthcare cost efficiencies.
(Logo: http://photos.prnewswire.com/prnh/20081117/FSLOGO)
“A majority of hospital-acquired infections contracted each year
originate with the colonization of bacteria on implantable medical
devices, which provide a good surface for bacterial growth,” said
Frost & Sullivan Research Analyst Prasanna Vadhana. “Owing to
the rapid growth in the use of medical device implants and the lack
of improved surface technologies, the medical device industry is in
dire need of next-generation devices that significantly improve
patient outcomes.”
To meet this need, Semprus BioSciences has developed the Semprus
Platform based on a bioinert, covalently-bonded surface
modification that reduces the attachment of bacteria, fungus,
platelets and blood proteins to a device.
“Semprus BioSciences’ platform is able to adapt to diverse
substrates such as polyurethane, silicone and titanium, thus paving
the way for next-generation products with improved clinical
benefits across the medical spectrum,” said Vadhana. “The
versatility of this technology creates avenues to address multiple
products ranging from contact lenses and orthopedic fixation
devices to hernia repair meshes and pacemakers, and many
others.”
In December 2010, Semprus BioSciences completed an $18 million
Series B financing co-led by SR One, the corporate venture capital
arm of GlaxoSmithKline, and Fo
‘/>”/>
